Senior Director, US Patient Marketing

Who We Are

Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life‑changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.

We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late‑stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X‑TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026.

Our Phase 3 epilepsy program also includes a second FOS study, X‑TOLE3, which would support regulatory submissions outside the U.S., and the X‑ACKT study in primary generalized tonic‑clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X‑NOVA clinical trial.

In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting, and continue to advance an early‑stage pipeline of novel therapeutic candidates. In 2025, we initiated Phase 1 trials for XEN
1701 (targeting Nav
1.7) and XEN
1120 (targeting Kv7). Nav
1.7 and Kv7 are important pain targets, and data from these Phase 1 studies are expected in 2026 to support Phase 2 proof‑of‑concept studies in acute pain. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.

We are seeking an experienced Senior Director, US Patient Marketing to lead the development and execution of a comprehensive, patient‑centered marketing strategy in support of Xenon’s first commercial launch and future growth.

This role will be a senior member of the US Marketing organization and will be accountable for shaping the U.S. patient and caregiver brand strategy, ensuring a seamless, compliant, and impactful patient experience from disease awareness through long‑term treatment engagement.

The Senior Director will build and lead a high‑performing Patient Marketing team and partner closely with Patient Services, Advocacy, Medical Affairs, Market Access, Legal, Regulatory, and Commercial leadership to ensure alignment, execution excellence, and meaningful impact for patients and caregivers.

This position reports to the Vice President, Marketing and will be based out of Boston, MA, USA in our Needham office. We will consider remote locations for exceptional candidates. The level of the position will be commensurate with the candidate’s education and industry experience. Hybrid positions require a minimum of two onsite days per week.

• Patient & Caregiver Strategy
  • Lead the development of a comprehensive U.S. patient and caregiver marketing strategy, including unbranded disease education and branded patient engagement initiatives
  • Define patient and caregiver value propositions, journey frameworks, and engagement strategies across the continuum of care
  • Ensure a deeply patient‑centric approach that reflects real‑world needs, barriers, and lived experiences
• Launch Planning & Execution
  • Serve as the Patient Marketing lead for U.S. launch readiness, ensuring patient programs, materials, and services are launch‑ready
  • Partner with cross‑functional launch teams to integrate patient marketing into overall brand and launch strategy
  • Develop phased launch plans that evolve from pre‑launch education through post‑launch activation and adherence support
• Integrated Patient…